TARDBP and Alzheimer disease: The use of neuropathological data would also allow investigating whether any of these biomarkers might be useful for detecting other common co‐pathologies observed in AD patients, such as Lewy bodies or TAR DNA‐binding protein 43 (TDP‐43; Hansson, 2021; Smirnov et al, 2022).